172 related articles for article (PubMed ID: 12921946)
1. Rituximab in combination with vinorelbine/gemcitabine chemotherapy in patients with primary refractory or early relapsed T cell rich B cell lymphoma. A pilot study.
Xiros N; Economopoulos T; Valsami S; Rontogianni D; Fountzilas G; Raptis S
Leuk Res; 2003 Dec; 27(12):1097-9. PubMed ID: 12921946
[TBL] [Abstract][Full Text] [Related]
2. Gemcitabine, ifosfamide, oxaliplatin and rituximab (R-GIFOX), a new effective cytoreductive/mobilizing salvage regimen for relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a pilot study.
Corazzelli G; Russo F; Capobianco G; Marcacci G; Della Cioppa P; Pinto A
Ann Oncol; 2006 May; 17 Suppl 4():iv18-24. PubMed ID: 16702180
[TBL] [Abstract][Full Text] [Related]
3. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
4. Rituximab-mediated sensitization of B-non-Hodgkin's lymphoma (NHL) to cytotoxicity induced by paclitaxel, gemcitabine, and vinorelbine.
Emmanouilides C; Jazirehi AR; Bonavida B
Cancer Biother Radiopharm; 2002 Dec; 17(6):621-30. PubMed ID: 12537665
[TBL] [Abstract][Full Text] [Related]
5. Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy.
El Gnaoui T; Dupuis J; Belhadj K; Jais JP; Rahmouni A; Copie-Bergman C; Gaillard I; Diviné M; Tabah-Fisch I; Reyes F; Haioun C
Ann Oncol; 2007 Aug; 18(8):1363-8. PubMed ID: 17496309
[TBL] [Abstract][Full Text] [Related]
6. Vinorelbine, gemcitabine, procarbazine and prednisone (ViGePP) as salvage therapy in relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL): results of a phase II study conducted by the Gruppo Italiano per lo Studio dei Linfomi.
Di Renzo N; Brugiatelli M; Montanini A; Vigliotti ML; Cervetti G; Liberati AM; Luminari S; Spedini P; Giglio G; Federico M
Leuk Lymphoma; 2006 Mar; 47(3):473-9. PubMed ID: 16396771
[TBL] [Abstract][Full Text] [Related]
7. Combination chemotherapy with gemcitabine and vinorelbine in the treatment of relapsed or refractory diffuse large B-cell lymphoma: a phase-II trial by the Hellenic Cooperative Oncology Group.
Papageorgiou ES; Tsirigotis P; Dimopoulos M; Pavlidis N; Fountzilas G; Papageorgiou S; Economopoulos T;
Eur J Haematol; 2005 Aug; 75(2):124-9. PubMed ID: 16000128
[TBL] [Abstract][Full Text] [Related]
8. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study.
Coiffier B; Haioun C; Ketterer N; Engert A; Tilly H; Ma D; Johnson P; Lister A; Feuring-Buske M; Radford JA; Capdeville R; Diehl V; Reyes F
Blood; 1998 Sep; 92(6):1927-32. PubMed ID: 9731049
[TBL] [Abstract][Full Text] [Related]
9. Rituximab-EPOCH, an effective salvage therapy for relapsed, refractory or transformed B-cell lymphomas: results of a phase II study.
Jermann M; Jost LM; Taverna Ch; Jacky E; Honegger HP; Betticher DC; Egli F; Kroner T; Stahel RA
Ann Oncol; 2004 Mar; 15(3):511-6. PubMed ID: 14998858
[TBL] [Abstract][Full Text] [Related]
10. Pilot study of an outpatient-based approach for advanced lymphoma using vinorelbine, gemcitabine and filgrastim.
Spencer A; Reed K; Arthur C
Intern Med J; 2007 Nov; 37(11):760-6. PubMed ID: 17542998
[TBL] [Abstract][Full Text] [Related]
11. Gemcitabine and vinorelbine combination is effective in both as a salvage and mobilization regimen in relapsed or refractory Hodgkin lymphoma prior to ASCT.
Suyanı E; Sucak GT; Akı ŞZ; Yeğin ZA; Özkurt ZN; Yağcı M
Ann Hematol; 2011 Jun; 90(6):685-91. PubMed ID: 21072518
[TBL] [Abstract][Full Text] [Related]
12. Long-term results of gemcitabine plus oxaliplatin with and without rituximab as salvage treatment for transplant-ineligible patients with refractory/relapsing B-cell lymphoma.
Corazzelli G; Capobianco G; Arcamone M; Ballerini PF; Iannitto E; Russo F; Frigeri F; Becchimanzi C; Marcacci G; De Chiara A; Pinto A
Cancer Chemother Pharmacol; 2009 Oct; 64(5):907-16. PubMed ID: 19219604
[TBL] [Abstract][Full Text] [Related]
13. A multicentre phase-II feasibility study evaluating gemcitabine/vinorelbine / prednisolone combination chemotherapy in relapsed / refractory Hodgkin's lymphoma.
Naqi N; Ahmad S; Shah I; Khattak J
J Coll Physicians Surg Pak; 2013 Jun; 23(6):397-400. PubMed ID: 23763798
[TBL] [Abstract][Full Text] [Related]
14. A multicenter phase 2 study of risk-adjusted salvage chemotherapy incorporating vinorelbine and gemcitabine for relapsed and refractory lymphoma.
Pasricha SR; Grigg A; Catalano J; Leahy M; Underhill C; Arthur C; D'Rozario J; Lowenthal R; Reed K; Spencer A
Cancer; 2008 Dec; 113(11):3192-8. PubMed ID: 18932253
[TBL] [Abstract][Full Text] [Related]
15. [Rituximab combined with second line regimens for treatment of seven relapsed and refractory Hodgkin lymphoma patients].
Liu H; Li H; Xiong W; Yi S; Zou D; Qiu L
Zhonghua Xue Ye Xue Za Zhi; 2015 Jul; 36(7):578-82. PubMed ID: 26304082
[TBL] [Abstract][Full Text] [Related]
16. Rituximab, gemcitabine, cisplatin, and dexamethasone in patients with refractory or relapsed aggressive B-cell lymphoma.
Hou Y; Wang HQ; Ba Y
Med Oncol; 2012 Dec; 29(4):2409-16. PubMed ID: 22476761
[TBL] [Abstract][Full Text] [Related]
17. Combination chemotherapy with gemcitabine and vinorelbine in the treatment of patients with relapsed or refractory small cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network.
Hainsworth JD; Burris HA; Erland JB; Baker M; Scullin DC; Shaffer DW; Greco FA;
Cancer Invest; 2003 Apr; 21(2):193-9. PubMed ID: 12743984
[TBL] [Abstract][Full Text] [Related]
18. Gemcitabine and vinorelbine chemotherapy for refractory or relapsing aggressive non-Hodgkin lymphoma.
Sivam V; Cook L; Hughes G; Karadimitris A; Marks AJ; Matthey F; Naresh KN; Szydlo RM; Yarranton H; Kanfer EJ; Macdonald DH
Hematol Oncol; 2012 Dec; 30(4):214-5. PubMed ID: 22422565
[No Abstract] [Full Text] [Related]
19. Results of a Phase II trial of gemcitabine, mitoxantrone, and rituximab in relapsed or refractory mantle cell lymphoma.
Garbo LE; Flynn PJ; MacRae MA; Rauch MA; Wang Y; Kolibaba KS
Invest New Drugs; 2009 Oct; 27(5):476-81. PubMed ID: 18953490
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of gemcitabine, carboplatin, dexamethasone, and rituximab in patients with relapsed/refractory lymphoma: a prospective multi-center phase II study by the Puget Sound Oncology Consortium.
Gopal AK; Press OW; Shustov AR; Petersdorf SH; Gooley TA; Daniels JT; Garrison MA; Gjerset GF; Lonergan M; Murphy AE; Smith JC; Pagel JM
Leuk Lymphoma; 2010 Aug; 51(8):1523-9. PubMed ID: 20578815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
